A billionaire investor of Athira Pharma is calling for the ouster of the Seattle company’s CEO and nominated himself and the former chief financial officer at Novartis for the board of directors.

Athira Pharma, Inc. Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 ...

Athira Pharma, a small drugmaker focused on neuroscience, is looking into the different paths it could take to “maximizing stockholder value,” after the company’s most advanced experimental ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their Options New York, New York ...

Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.. Athira, which went public in 2020, is ...

Athira Pharma’s experimental Alzheimer’s disease drug has failed a Phase 2 clinical trial and the working theory as to why is that the small molecule does not play well with widely prescribed ...

However, Athira said ADAS-Cog11 and ADCS-ADL23 “directionally favored fosgonimeton treatment,” with a nonsignificant difference of 0.70 on the cognition scale and 0.67 on the function score.

Athira had clung to the hope that its experimental drug fosgonimeton could overcome a phase 2 failure in Alzheimer’s to demonstrate success in Parkinson’s and dementia. Unfortunately, a mid ...

Athira Pharma’s stock plummeted nearly 70% Wednesday after a clinical trial testing its candidate drug for Alzheimer’s disease failed to meet its primary endpoint.. The phase 2 trial enrolled ...

Athira Pharma is aiming to go public. The Seattle biotech filed initial IPO paperwork Wednesday, a surprising move that would give the company additional capital to develop its therapies for brain ...

Athira priced its IPO on Thursday at $17 per share, which came in at the high end of its range.The company sold 12 million shares and raised $204 million in the IPO. The stock was up slightly in ...